Minister for Health, Simon Harris has launched a new guideline aimed at improving the quality and safety of treating Type 1 Diabetes. The National Clinical Effectiveness Committee Guideline is the first to be developed in Ireland using the UK’s National Institute for Health and Care Excellence (NICE) contextualisation process; whereby a recent NICE guideline is adapted for use in another country. The recommendations are based on the best research evidence and on national and international clinical expertise. This initiative was led by a group from the Health Service Executive’s (HSE) National Clinical Programme on Diabetes, supported by the Department’s Clinical Effectiveness Unit and a team from NICE. The guideline was quality assured by the National Clinical Effectiveness Committee (NCEC). Type 1 diabetes is an autoimmune condition that causes destruction of the insulin producing cells in the pancreas. This means that people with type 1 diabetes must self-inject insulin in order to manage their blood glucose and avoid a range of serious short and long-term complications.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
